3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow AZD4017: new trials by email Literature Review of AZD4017 trials Research Report on AZD4017
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) AZD4017, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Completed | University of Leeds | 28 | 2018-04-10 | 2019-03-22 |
| Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. AZD4017, Placebo - Idiopathic Intracranial Hypertension | Phase 2 | Completed | University of Birmingham | 31 | 2014-04-25 | 2021-10-27 |
| A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure AZD4017, Placebo - Raised Intraocular Pressure | Phase 2 | Completed | AstraZeneca | 50 | 2010-12-01 | 2014-02-14 |
Blindness (1) · Diabetes Mellitus, Type 2 (1) · Headache (1) · Intracranial Hypertension (1) · Obesity (1) · Ocular Hypertension (1) · Papilledema (1) · Pseudotumor Cerebri (1) · Tinnitus (1)
AstraZeneca (1) · University of Birmingham (1) · University of Leeds (1)
United Kingdom (3) · Sweden (1) · United States (1)
Alexandra Sinclair, MbChb PhD (1) · Heather Bryson, PhD (1) · Tony Ho, MD (1)